BIO-RAD LABORATORIES, INC. acquired QuantaLife, Inc. for $179.4 million fair value of consideration ($150.3 million cash at closing, $5.0 million holdback, $24.1 million contingent consideration; contingent portion could reach $48 million on sales and development milestones), a transaction completed in October 2011, structured as all cash plus contingent consideration.
QuantaLife, Inc. operates in Life Science. QuantaLife developed droplet digital PCR technology that became the foundation of Bio-Rad's droplet digital PCR (ddPCR) systems.
QuantaLife's droplet digital PCR technology formed the core of Bio-Rad's ddPCR product line.
Pioneering droplet digital PCR platform that established Bio-Rad's ddPCR franchise. Launched Bio-Rad's droplet digital PCR (ddPCR) product line within the Life Science segment. Life Science segment
In October 2011, we acquired all the issued and outstanding stock of QuantaLife, Inc. The fair value of the consideration as of the acquisition date was $179.4 million, which comprised of $150.3 million paid in cash at the closing date, a $5.0 million holdback... and $24.1 million in contingent consideration.Bio-Rad Laboratories FY2011 10-K, acquisitions disclosure
Advisory firms were not disclosed for this transaction.